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Abstract
Background: In newly diagnosed patients with Hodgkin lymphoma (HL) the effect of doxorubicin, bleomycin,
vinblastine and dacarbazine (ABVD)-related neutropenia on chemotherapy delivery is poorly documented. The aim
of this analysis was to assess the impact of chemotherapy-induced neutropenia (CIN) on ABVD chemotherapy
delivery in HL patients.
Study design: Data from two similarly designed, prospective, observational studies conducted in the US and the
EU were analysed. One hundred and fifteen HL patients who started a new course of ABVD during 2002-2005 were
included. The primary objective was to document the effect of neutropenic complications on delivery of ABVD
chemotherapy in HL patients. Secondary objectives were to investigate the incidence of CIN and febrile
neutropenia (FN) and to compare US and EU practice with ABVD therapy in HL. Pooled data were analysed to
explore univariate associations with neutropenic events.
Results: Chemotherapy delivery was suboptimal (with a relative dose intensity ≤ 85%) in 18-22% of patients. The
incidence of grade 4 CIN in cycles 1-4 was lower in US patients (US 24% vs. EU 32%). Patients in both the US and
the EU experienced similar rates of FN across cycles 1-4 (US 12% vs. EU 11%). Use of primary colony-stimulating
factor (CSF) prophylaxis and of any CSF was more common in the US than the EU (37% vs. 4% and 78% vs. 38%,
respectively). The relative risk (RR) of dose delays was 1.54 (95% confidence interval [CI] 1.08-2.23, p = 0.036) for
patients with vs. without grade 4 CIN and the RR of grade 4 CIN was 0.35 (95% CI 0.12-1.06, p = 0.046) for patients
with vs. without primary CSF prophylaxis.
Conclusions: In this population of HL patients, CIN was frequent and FN occurrence clinically relevant.
Chemotherapy delivery was suboptimal. CSF prophylaxis appeared to reduce CIN rates.
Introduction
Combination therapy with doxorubicin, bleomycin, vin-
blastine and dacarbazine (ABVD) is the standard che-
motherapy regimen for patients with Hodgkin
lymphoma (HL) [1-3]. Myelosuppression, in particular
neutropenia, is common during ABVD treatment [2].
Chemotherapy-induced neutropenia (CIN) can lead to
febrile neutropenia (FN), which is associated with con-
siderable morbidity, mortality and costs [4]. Standard
care for the majority of FN patients requires hospitalisa-
tion and administration of intravenous antibiotics [5,6].
Neutropenic events often result in dose delays and
dose reductions, leading to impaired chemotherapy
delivery which has been associated with decreased survi-
val in certain types of cancer [7-10], indicating that opti-
mal intensity of chemotherapy treatment can improve
patient outcomes [8]. Colony-stimulating factors (CSFs)
have been shown to reduce the incidence and severity of
neutropenic events across a broad range of malignancies
and regimens and also to support the delivery of full
chemotherapy dose intensity [5,11].
In patients with HL, the effect of ABVD-related neu-
tropenia and neutropenic complications on chemother-
apy delivery are poorly documented [2,12]. Two
similarly designed, prospective, observational studies
were conducted in the US [13] and Europe [14] to
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going chemotherapy. Here we present a subgroup analy-
sis of HL patients from these studies. The primary
objective was to assess the effects of neutropenic com-
plications on the delivery of ABVD chemotherapy. Sec-
ondary objectives were to investigate the incidence of
CIN and FN in patients with HL undergoing ABVD
chemotherapy and to compare US and EU practice with
ABVD therapy in HL.
Methods
Two similarly designed, prospective, observational stu-
dies [13,14] enrolled patients with solid tumours or lym-
phoma initiating a new course of chemotherapy, with at
least 4 cycles planned, during the period 2002-2005. In
the US, a total of 4458 patients were recruited from 115
community practices. In the EU, a total of 749 patients
were recruited from 66 clinical centres in Belgium,
France, Germany, Spain and the UK.
Patients eligible for inclusion in this subgroup analysis
were adults aged ≥ 18 years about to start a new course
of ABVD (patients in whom doxorubicin was replaced
with epirubicin were also allowed). In the US study,
patients had a minimum life expectancy of at least 3
months. In the EU study, patients had to be HL stage
IB-IV. Prior chemotherapy and concurrent radiation
therapy were permitted. Key exclusion criteria were: use
of antibody-based or cell-based immunotherapies, a his-
tory of stem-cell or bone-marrow transplantation and
HIV infection. Additionally, the US study excluded
patients diagnosed with myeloma or treated for active
infection and did not allow participation in double-blind
clinical trials. Patients in the EU were excluded if they
had conditions causing neutropenia, malignant condi-
tions with myeloid characteristics, or active infection
within 72 hours prior to the start of chemotherapy.
Concurrent participation in phase I/II clinical trials was
not permitted. Ethical approval was obtained for all cen-
tres and all participants provided informed consent.
Data were merged and variable definitions reconciled
to form a single, pooled dataset. Body surface area was
calculated using the Mosteller formula [15]. Delivery of
chemotherapy was assessed by considering the propor-
tion of patients that received relative dose intensity
(RDI) ≤ 85% of the planned or standard dose intensity
and by documenting the occurrence of dose reductions
> 10% and dose delays > 3 days. As delivery of vinblas-
tine is unlikely to be affected by neutropenia, this agent
was excluded from the calculation of RDI and dose
reductions. In the US study, blood counts were drawn
at the beginning of each cycle and at mid-cycle, for up
to 4 cycles of treatment. In the EU study, a blood count
at the expected (protocol defined) absolute neutrophil
count (ANC) nadir was required in cycle 1. Centres
were also required to record all blood counts taken dur-
ing each patient’s chemotherapy treatment. Grades 3
and 4 CIN were defined as an ANC < 1000/mm
3 and
< 500/mm
3 [16], respectively, and FN as ANC < 1000/
mm
3 in combination with site-reported fever above
38°C and/or infection. Primary CSF prophylaxis was
defined as CSF use in the first cycle of chemotherapy
before a documented grade 3-4 CIN occurred or
denoted as primary prophylaxis by the site.
Due to the limited sample size, analyses were predo-
minantly descriptive. Univariate associations between
variables were explored in the pooled dataset. Associa-
tions of binary data were expressed as relative risks with
accompanying 95% confidence intervals. Significance
testing was based on Fisher’s exact test (2-sided) due to
small sample size, which explains some apparent incon-
sistencies between p values and confidence limits.
Results
Patient characteristics
A total of 115 HL patients (68 US patients, 47 EU
patients) met the eligibility criteria and were included in
the analysis. The age range was 19-83 years (median 36)
in US patients and 18-74 years (median 34) in EU
patients; 49% of US patients and 38% of EU patients
were female. US patients had slightly higher body sur-
face area and higher incidence of stage III/IV disease
than EU patients and were more often pre-treated with
radiotherapy (Table 1). Eastern Cooperative Oncology
Group performance status was similar between US and
EU patients and no patients had prior chemotherapy.
Treatment characteristics
In most patients, 4-5 or 6 cycles of ABVD were planned.
In the US and the EU, median planned dose intensities
(expressed on the basis of actual body weight) met the
ABVD standard of bleomycin, 5 units/m
2/week; doxoru-
bicin, 12.5 mg/m
2/week; dacarbazine, 187.5 mg/m
2/week;
and vinblastine, 3 mg/m
2/week. Actual planned dose
intensities deviated in a number of patients and resulting
means were marginally higher in the EU patients (Table
1). One US patient (1.5%) and three EU patients (6.4%)
received epirubicin instead of doxorubicin (EBVD).
The percentage of patients receiving CSF overall and as
primary prophylaxis was higher for US patients (any CSF
use: US 78% vs. EU 38%; primary CSF prophylaxis: US
37% vs. EU 4%). Antibiotic use was similar between the
two populations (any antibiotic use: US 41% vs. EU 49%;
primary prophylaxis with antibiotics: US 13% vs. EU 17%).
Chemotherapy delivery
Dose delays > 3 days were more frequently observed in
EU patients and dose reductions > 10% were more fre-
quent in US patients (Figure 1). Chemotherapy delivery
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ABVD standard). Comparison against the actual planned
dose intensity for each individual patient led to a very
similar result.
Incidence of neutropenia and FN
Patients in both the US and the EU experienced similar
rates of FN in the first cycle of chemotherapy (US 7%
vs. EU 9% EU) and across cycles 1-4 (US 12% vs. EU
11%). The incidence of CIN in cycles 1-4 was lower in
US patients (Figure 2). US patients had a mean ANC
nadir of 2000 ± 2300/mm
3 in the first cycle compared
to EU patients whose mean ANC nadir was 1300 ±
1000/mm
3 in the first cycle.
Factors associated with chemotherapy delivery in the
pooled dataset
The relative risk (RR) of dose delays > 3 days was
1.54 (95% confidence interval [CI] 1.08-2.23, p =
0.036) for patients with vs. without grade 4 CIN.
There was no evidence of an association between the
presence of grade 4 CIN in any cycle and dose reduc-
tions > 10% or RDI ≤ 85% of planned/standard. Simi-
larly, there was no evidence of an association between
grade 4 CIN in cycle 1 and dose delays, dose reduc-
tions or RDI ≤ 85% of planned/standard. CSF primary
prophylaxis was not associated with dose delays > 3
days, dose reduction > 10% or RDI ≤ 85% of planned/
standard.
Table 1 Patient, disease and treatment characteristics
Characteristic US (N = 68) EU (N = 47)
Age in years, mean ± SD (range) 40.9 ± 16.2 (19-83) 37.9 ± 16.5 (18-74)
Female gender, N (%) 33 (48.5) 18 (38.3)
Race, N (%) Caucasian/white 54 (79.4) 46 (97.9)
Black 10 (14.7) 0 (0.0)
Other 4 (5.9) 1 (2.1)
BSA at baseline in m
2, mean ± SD (range) 1.94 ± 0.26 (1.42-2.53) 1.85 ± 0.21 (1.41-2.28)
ECOG status, N (%) 0 47 (69.1) 30 (63.8)
1 20 (29.4) 14 (29.8)
2 1 (1.5) 3 (6.4)
Disease stage
1, N (%) I 8 (12.1)
2 5 (10.6)
II 30 (45.5)
2 28 (59.6)
III 23 (34.8)
2 8 (17.0)
IV 5 (7.6)
2 6 (12.8)
Prior radiotherapy, N (%) 6 (8.8) 0 (0.0)
Baseline WBC in 10
3/mm
3, mean ± SD; median 9.4 ± 4.9; 7.8 9.5 ± 3.8; 8.4
Baseline ANC in 10
3/mm
3, mean ± SD; median 6.5 ± 3.3; 5.3
2 7.2 ± 3.6; 6.6
Diabetes, N (%) 8 (11.8) 0 (0.0)
Cardiac comorbidity, N (%) 0 (0.0) 2 (4.3)
Planned dose intensity in mg/m
2/week, mean ± SD; median
Bleomycin 4.9 ± 0.9; 4.9 5.3 ± 1.2; 5.0
Doxorubicin 12.5 ± 1.9; 12.3 12.8 ± 2.7; 12.4
3
Dacarbazine 184.0 ± 29.5; 183.6 198.3 ± 50.2; 186.7
Vinblastine 3.0 ± 0.5; 2.9 3.2 ± 0.8; 3.0
Planned cycle number, N (%) ≤ 3 0 (0.0) 2 (4.3)
4-5 29 (42.6) 16 (34.0)
6 38 (55.9) 26 (55.3)
≥ 8 1 (1.5) 3 (6.4)
Planned cycle length in days, N (%) 14 7 (10.3) 5 (10.6)
21 5 (7.4) 2 (4.3)
28 56 (82.4) 40 (85.1)
BSA body surface area; ECOG Eastern Cooperative Oncology Group; WBC white blood cell count; ANC absolute neutrophil count.
1 US: based on American Joint Committee Cancer staging; EU: based on Ann Arbor staging.
2 N = 66 due to missing values.
3N = 44 as 3 EU patients received epirubicin.
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the pooled dataset
Patients receiving CSF primary prophylaxis were less
likely to develop CIN than patients who did not receive
CSF primary prophylaxis. The RR of grade 4 CIN in any
cycle was 0.35 (95% CI 0.12-1.06, p = 0.046) for patients
with vs. without primary CSF prophylaxis, and the RR
of grade 3 or 4 CIN in any cycle was 0.42 (95% CI 0.23-
0.76, p < 0.001). There was also a reduced risk of grade
3 or 4 CIN in cycle 1 for patients with vs. without CSF
prophylaxis (RR 0.40, 95% CI 0.19-0.83, p = 0.004).
There was no evidence of an association between CSF
primary prophylaxis and incidence of FN in cycle 1 or
cycles 1-4. In cycle 1, FN incidence was 7% in 27
patients with CSF primary prophylaxis and 8% in 88
patients with no CSF primary prophylaxis (RR 0.93, 95%
CI 0.21-4.22, p = 1.000). In cycles 1-4, corresponding
incidences were 15% and 10% (RR 1.45, 95% CI 0.48-
4.33, p = 0.500). The other univariate associations con-
sidered were not statistically significant.
Discussion
This study assessed the impact of CIN on ABVD che-
motherapy delivery in HL patients in the EU and the
US. Baseline characteristics were similar in both groups
although US patients had a more advanced disease state.
In both EU and US patients, CIN occurrence was sub-
stantial and the observed FN incidence of 11-12% was
considerably higher than the 4% reported in current
European Organisation for Research and Treatment of
Cancer (EORTC) guidelines [5]. EORTC guidelines are
based on a literature review of clinical trial data and
under-reporting of febrile events has been noted to be
common in randomised controlled trials [17]. This
study is the first multi-centre investigation of neutrope-
nic event incidence in general populations of HL
patients treated with ABVD. Three retrospective single-
centre studies have also addressed this topic [18-20].
Populations studied were similar to ours with respect to
median age and grade 3/4 CIN risk per patient. How-
ever, grade 3/4 CIN risk per patient was not available
from Evens et al. [18], and in the single-physician
experience (with no CSF use) reported by Boleti and
Mead, the proportion of stage III-IV patients was only
13% [19]. Overall FN incidence was 10%, 5-9% and 5%
in the studies by Chand et al. (N = 81) [20], Evens et al.
(N = 84) [18] and Boleti and Mead (N = 38) [19],
respectively. These findings are not incompatible with
our results, considering that retrospective data may be
affected by incomplete recording. In addition, practice
patterns can differ, and chance effects may play a role in
small patient samples.
In both the US and EU populations, chemotherapy
delivery was suboptimal with 18-22% of patients receiv-
ing RDI ≤ 85% compared to standard/planned. As the
importance of ABVD dose intensity in determining
remission and survival has not yet been defined [2], the
clinical impact of this suboptimal ABVD delivery is not
known. However, the data highlight that impaired che-
motherapy delivery remains a problem in everyday clini-
cal practice, although single centres may achieve very
high average chemotherapy dose intensity [18]. Univari-
a t ea n a l y s i ss h o w e dt h a tg r a d e4C I Ni n c r e a s e dt h er i s k
of dose delays > 3 days; however, the small patient num-
bers in each data set did not allow for efficient
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Figure 1 Chemotherapy delivery in US and EU patients.
Incidence of dose delays > 3 days in any cycle, dose reductions >
10% in any drug in any cycle, and RDI ≤ 85% compared to either
planned RDI or standard ABVD in US (N = 68) and EU (N = 47)
patients during the first 4 cycles of chemotherapy. Error bars
represent 95% CIs. *Assessment took into account administered
cycles only;
¶Disregarding vinblastine;
‡EBVD patients excluded (US
N = 67, EU N = 44); Standard ABVD: bleomycin 5 units/m
2/week,
doxorubicin 12.5 mg/m
2/week, dacarbazine 187.5 mg/m
2/week,
vinblastine 3 mg/m
2/week. RDI relative dose intensity; ABVD
doxorubicin, bleomycin, vinblastine and dacarbazine; CI confidence
interval; EBVD epirubicin, bleomycin, vinblastine and dacarbazine.
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Figure 2 Incidence of neutropenic events in US and EU
patients. Incidence of grade 3 and 4 CIN and FN in US (N = 68)
and EU (N = 47) patients during the first 4 cycles of chemotherapy.
Patients with grade 4 CIN were not counted as having grade 3 CIN.
Error bars represent 95% CIs. CIN chemotherapy-induced
neutropenia; FN febrile neutropenia; CI confidence interval.
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tropenia and compromised chemotherapy delivery.
Moreover, due to incomplete timing information, we
could not clearly establish which dose delays and dose
reductions occurred before or after neutropenic events,
which may have diluted some associations. The influ-
ence of reduced or delayed chemotherapy delivery on
neutropenic event occurrence remains to be assessed in
HL patients receiving ABVD.
Use of primary CSF prophylaxis in ABVD patients was
more common in the US than the EU, and in the uni-
variate analysis performed, CSF prophylaxis was asso-
ciated with a reduced risk of grade 4 CIN. However, the
numbers of patients in each dataset were too small for
efficient multivariate analysis of CIN risk. Despite
greater CSF use and more dose reductions in the US
population, similar FN rates were observed between
patients in the EU and the US. This may be explained
by a more advanced disease state in US patients, which
has been identified as an adverse risk factor for
increased incidence of FN [5].
In summary, CIN was frequent and FN occurrence
clinically relevant in HL patients receiving ABVD che-
motherapy. Dose delays and dose reductions were fre-
quent and resulted in suboptimal delivery of
chemotherapy in approximately one fifth of patients.
Use of primary CSF prophylaxis was more common in
the US than the EU and appeared to reduce CIN rates.
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